Cerebraca Wafer ((Z)-n-butylidenephthalide/polymer wafer) / Everfront Biotech - LARVOL DELTA

Cerebraca-02/3: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma (clinicaltrials.gov) - P2/3 | N=175 | Not yet recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial completion date: Dec 2030 ➔ Dec 2029 | Initiation date: Nov 2026 ➔ Apr 2027 | Trial primary completion date: Dec 2028 ➔ Mar 2029

Trial completion date • Trial initiation date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Cerebraca-02/3: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma (clinicaltrials.gov) - P2/3 | N=175 | Not yet recruiting | Sponsor: Everfront Biotech Co., Ltd.

New P2/3 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1/2 | N=22 | Completed | Sponsor: Everfront Biotech Co., Ltd. | Active, not recruiting ➔ Completed | N=36 ➔ 22 | Trial completion date: Dec 2024 ➔ Sep 2024

Enrollment change • Trial completion • Trial completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1/2 | N=36 | Active, not recruiting | Sponsor: Everfront Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Apr 2023

Enrollment closed • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor